IGC Pharma

We are pleased to announce that IGC Pharma will participate in #BIOPartneringJPM held in conjunction with the 43rd Annual #JPMorganHealthcareConference on January 13-16, 2025. Our team will meet with #investors and partners to discuss our recent achievements, upcoming #milestones, and what's next for IGC Pharma. Let's get in touch! We'd love to talk and explore new #opportunities together. Please contact us to set up a meeting: igc@imsinvestorrelations.com   See full information here: https://lnkd.in/eyESSDRx   #IGCPharma #JPM2025 #BioPartnering #HealthcareInnovation #PharmaProgress #JPMWeek

Advancing #Hope in #Alzheimer’sCare At IGC Pharma, we’re driving #innovation with IGC-AD1, an investigational therapy tackling #cognitivedecline and disease markers like #amyloidplaques and #tautangles   Interim #Phase2 Highlights: #Improvedcognition and #reducedagitation. As we prepare for new trials in 2025, we’re excited to be moving closer to transforming Alzheimer’s care.   Read the full article here: https://lnkd.in/ezgfXg3T   #AlzheimersResearch #IGCPharma #CognitiveHealth #InnovationInMedicine

Advancing #Alzheimer’s Treatment   While reducing #agitation remains the Phase 2 trial’s primary outcome, the cognition results are exploratory and underscore IGC-AD1’s potential to target #diseaseprogression.   Read the full article here: https://lnkd.in/eSSRemqy   #AlzheimersResearch #Innovation #ClinicalTrials #IGCPharma #HealthcareTransformation

The #EndocannabinoidSystem and #ImmuneHealth: A Powerful Connection The Endocannabinoid System (#ECS) plays a vital role in regulating #ImmuneResponses and #managingInflammation, offering exciting therapeutic potential for conditions like #MultipleSclerosis, #Crohn’sDisease, and #RheumatoidArthritis.   In this insightful piece, Dr. Saadia Shahnawaz, in collaboration with IGC Pharma, explores how targeting the ECS could revolutionize #treatments for Immune-Related #Diseases and restore balance to the #ImmuneSystem.   Learn more about the Science behind this #GroundbreakingResearch. https://lnkd.in/e_aPn3fb #AlzheimersResearch, #IGCPharma, #HealthcareInnovation

IGC Pharma Q2 FY2025: Advancing #Alzheimer’s #Research & Delivering Results   We’re proud to report significant progress this quarter as we continue our mission to reshape Alzheimer’s care and expand #innovative #treatment options.   Highlights:   Promising Results in Alzheimer’s Research: #Preclinical findings for IGC-AD1 show notable effects on #taupathology, with potential to modify the #disease and address symptoms. Pipeline Progress: IGC-AD1 advances toward #clinicaltrials, while new insights from #AImodeling strengthen our position in Alzheimer’s and GLP-1 agonist research. #FinancialGrowth: A 42% #revenue increase driven by U.S. projects, alongside a 25% decrease in SG&A expenses. Our team’s dedication is transforming #healthcare solutions for the future. Thank you to everyone supporting our journey! Read full article here: https://lnkd.in/e3WjAt_Z #AlzheimersResearch #IGCPharma #HealthcareInnovation

IGC Pharma's Strategic Expansion: A Deep Dive with CEO Ram Mukunda   We’re excited to share the latest insights from our CEO, Ram Mukunda, in his recent interview for the IMS Investor Relations Spotlight Series.   In this conversation, Ram delves into IGC’s strategic direction in expanding into #neurological and #metabolichealth, highlighting how GLP-1 agonists could make a meaningful impact on both #Alzheimer’s treatments and #weightmanagement. He also provides an update on IGC-AD1, our promising Phase 2 candidate that’s showing potential to address #agitation in Alzheimer’s #dementia. Additionally, Ram explains how we’re leveraging #artificialintelligence to diversify our pipeline and enhance #patient outcomes.   Read the full interview to learn more about IGC Pharma’s innovative vision: https://lnkd.in/eK9QUSH9   #IGCPharma #HealthInnovation #PharmaIndustry #DrugDiscovery #AIinHealthcare #Alzheimers #WeightManagement #GLP1Agonists

Exciting news from IGC Pharma! We are pleased to announce the expansion of our #Phase2 #clinicaltrial for IGC-AD1 to Baycrest in Toronto, marking a key milestone in the fight against #Alzheimer's-related #agitation. Baycrest, a global leader in #brainhealth and aging, has enrolled its first #patients in this groundbreaking trial. With 13 additional sites across North America, we are committed to advancing innovative #treatments that could significantly improve the #qualityoflife for patients and their #caregivers. More info here: https://lnkd.in/eVDiwPgY   #AlzheimersResearch #IGCPharma #Baycrest #ClinicalTrials #BrainHealth #PatientCare #InnovationInHealth #Neurology #DementiaCare

#Alzheimer’s #research is reaching new heights, with billions invested and the #FDA recently approving two groundbreaking new drugs. At IGC Pharma, we’re honored to work alongside the late Dr. Lopera, Dr. Aguillon and the GNA - Grupo de Neurociencias de Antioquia, driving forward research to improve the quality of life for Alzheimer’s patients. This video is just a teaser, offering a glimpse into the #inspiring stories and advancements we’ve made. The full story will be revealed in our upcoming documentary, where we dive deeper into the groundbreaking work being done. Stay tuned—there’s so much more to come. Together, we’re bringing #hope to #patients and their families. #AlzheimersResearch #IGCPharma #Neuroscience #HopeForAlzheimers Ram Mukunda Claudia Grimaldi Evelyn Gutiérrez . Thanks! Gustavo Dallmeier

IGC Pharma Wins Two Awards for Alzheimer’s Research! We are thrilled to announce that IGC Pharma has received Third Prize and the Disproportionate Impact Prize in the #NIA's PREPARE Challenge! Our #AI-driven research is paving the way for #earlyprediction tools for Alzheimer’s, with the goal of detecting #cognitivedecline up to 20 years before symptoms appear. Learn more about the Phase 1 winners and top datasets used in the challenge here: https://lnkd.in/eERe624E A special congratulations to the dedicated team who made this achievement possible: Paola Ruiz Puentes, Daniel Andrés Crovo Pérez, Néstor González, Pablo Arbeláez (https://lnkd.in/eZMZmaMd), Maria Juanita Arbelaez Duarte, Maria Alejandra Tanagrife, and Evelyn Gutiérrez. Your hard work and commitment are making a difference! At IGC Pharma, we are committed to improving patient outcomes, reducing the caregiving burden, and creating lasting value for patients, #caregivers, and #healthcaresystems. #AlzheimersResearch #AI #HealthcareInnovation #IGCPharma #PREPAREChallenge

Episode 4: Compassionate Message: We at IGC Pharma are deeply grateful to everyone who has followed this powerful story. In the face of #Alzheimer's, love and compassion are our greatest strengths. Mariangela’s heartfelt message reminds us to cherish every moment with our loved ones. Your support and attention make a #world of difference as we continue to raise awareness and spread hope for those affected by this #disease. Together, we can make strides towards better care, understanding, and treatment. #AlzheimersAwareness #HopeForACure #IGCPharma